<VariationArchive VariationID="832602" VariationName="NC_000016.10:g.(?_71569834)_(71576435_?)del" VariationType="Deletion" Accession="VCV000832602" Version="7" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2020-04-15" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="820870" VariationID="832602">
      <GeneList>
        <Gene Symbol="TAT" FullName="tyrosine aminotransferase" GeneID="6898" HGNC_ID="HGNC:11573" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16q22.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="71565660" stop="71577092" display_start="71565660" display_stop="71577092" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="71600753" stop="71610997" display_start="71600753" display_stop="71610997" Strand="-" />
          </Location>
          <OMIM>613018</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000016.10:g.(?_71569834)_(71576435_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16q22.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="71603737" innerStop="71610338" display_start="71603737" display_stop="71610338" variantLength="6602" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_71603737)_(71610338_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_71603737)_(71610338_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.10:g.(?_71569834)_(71576435_?)del AND Tyrosinemia type II" Accession="RCV001033077" Version="7">
        <ClassifiedConditionList TraitSetID="110">
          <ClassifiedCondition DB="MedGen" ID="C0268487">Tyrosinemia type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-08-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-08-22" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9544843</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="110" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5080" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Tyrosinemia type II</ElementValue>
                <XRef ID="MONDO:0010160" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Richner Hanhart syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">TAT deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosine transaminase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Keratosis palmoplantaris with corneal dystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Oregon type tyrosinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosinosis oculocutaneous type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosine aminotransferase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Oculocutaneous tyrosinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosinemia type 2</ElementValue>
                <XRef ID="Tyrosinemia+type+2/7282" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TYRSN2</ElementValue>
                <XRef Type="MIM" ID="276600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3105" />
                <XRef ID="3105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tyrosine.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Tyrosine, Tyrosinemia, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tryosine-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Tyrosine Elevated, Succinylacetone Normal, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tyrosine-Normal-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Tyrosine Normal/Elevated, Succinylacetone Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="28378" DB="Orphanet" />
              <XRef ID="C0268487" DB="MedGen" />
              <XRef ID="MONDO:0010160" DB="MONDO" />
              <XRef Type="MIM" ID="276600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2357640" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="NM_000353.2_16_Deletion (exons 2-10)|MedGen:C0268487" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001196384" DateUpdated="2024-06-09" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-08-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9544843</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in TAT are known to be pathogenic (PMID: 9544843). This variant has been observed in an individual affected with TAT-related conditions (Invitae). This variant is a gross deletion of the genomic region encompassing exons 2-10 of the TAT gene, which includes the initiator codon. The 5' end of this event is unknown as it extends beyond the assayed region for this gene and therefore may encompass additional genes. The 3' boundary is likely confined to intron 10 of the TAT gene. This is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_71603737)_(71610338_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268487" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2357640" TraitType="Disease" MappingType="XRef" MappingValue="C0268487" MappingRef="MedGen">
        <MedGen CUI="C0268487" Name="Tyrosinemia type II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

